# Caris Life Sciences, Inc.: financial statements, quarterly

CAI · Nasdaq · CIK 2019410 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cai.md) · [Financials](/companies/cai/financials.md) · [Filings](/companies/cai/filings.md) · [Insiders](/companies/cai/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cai/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [100](/filings/0002019410-25-000012.md) | [102](/filings/0002019410-25-000028.md) | [130 d](/filings/0002019410-26-000016.md) | [121](/filings/0002019410-26-000044.md) | [181](/filings/0002019410-26-000055.md) | [217](/filings/0002019410-25-000028.md) | [293 d](/filings/0002019410-26-000016.md) | [216](/filings/0002019410-26-000044.md) | [264](/filings/0002019410-26-000055.md) |
| Research and development | $m | [24.8](/filings/0002019410-25-000012.md) | [27.6](/filings/0002019410-25-000028.md) | [27.1 d](/filings/0002019410-26-000016.md) | [23.1](/filings/0002019410-26-000044.md) | [25.0](/filings/0002019410-26-000055.md) | [21.6](/filings/0002019410-25-000028.md) | [31.8 d](/filings/0002019410-26-000016.md) | [31.3](/filings/0002019410-26-000044.md) | [32.4](/filings/0002019410-26-000055.md) |
| Operating income | $m | [(67.0)](/filings/0002019410-25-000012.md) | [(60.8)](/filings/0002019410-25-000028.md) | [(37.0) d](/filings/0002019410-26-000016.md) | [(58.0)](/filings/0002019410-26-000044.md) | [(18.0)](/filings/0002019410-26-000055.md) | [32.6](/filings/0002019410-25-000028.md) | [88.4 d](/filings/0002019410-26-000016.md) | [5.3](/filings/0002019410-26-000044.md) | [26.9](/filings/0002019410-26-000055.md) |
| Interest expense | $m | [13.7](/filings/0002019410-25-000012.md) | [13.8](/filings/0002019410-25-000028.md) | [13.3 d](/filings/0002019410-26-000016.md) | [12.8](/filings/0002019410-26-000044.md) | [19.2](/filings/0002019410-26-000055.md) | [13.5](/filings/0002019410-25-000028.md) | [11.4 d](/filings/0002019410-26-000016.md) | [12.8](/filings/0002019410-26-000044.md) | [9.2](/filings/0002019410-26-000055.md) |
| Income tax | $m | [0.0](/filings/0002019410-25-000012.md) | [0.0](/filings/0002019410-25-000028.md) | [0.0 d](/filings/0002019410-26-000016.md) | [0.0](/filings/0002019410-26-000044.md) | [0.0](/filings/0002019410-26-000055.md) | [0.0](/filings/0002019410-25-000028.md) | [0.0 d](/filings/0002019410-26-000016.md) | [(0.1)](/filings/0002019410-26-000044.md) | [0.0](/filings/0002019410-26-000055.md) |
| Net income | $m | [(66.2)](/filings/0002019410-25-000012.md) | [(67.7)](/filings/0002019410-25-000028.md) | [(36.9) d](/filings/0002019410-26-000016.md) | [(103)](/filings/0002019410-26-000044.md) | [(71.8)](/filings/0002019410-26-000055.md) | [24.3](/filings/0002019410-25-000028.md) | [82.0 d](/filings/0002019410-26-000016.md) | [(0.5)](/filings/0002019410-26-000044.md) | [(0.6)](/filings/0002019410-26-000055.md) |
| Diluted EPS | $ per share | [(2.54)](/filings/0002019410-25-000012.md) | [(2.59)](/filings/0002019410-25-000028.md) | not reported | [(3.57)](/filings/0002019410-26-000044.md) | [(7.97)](/filings/0002019410-26-000055.md) | [0.08](/filings/0002019410-25-000028.md) | not reported | [0.00](/filings/0002019410-26-000044.md) | [0.00](/filings/0002019410-26-000055.md) |
| Basic EPS | $ per share | [(2.54)](/filings/0002019410-25-000012.md) | [(2.59)](/filings/0002019410-25-000028.md) | not reported | [(3.57)](/filings/0002019410-26-000044.md) | [(7.97)](/filings/0002019410-26-000055.md) | [0.09](/filings/0002019410-25-000028.md) | not reported | [0.00](/filings/0002019410-26-000044.md) | [0.00](/filings/0002019410-26-000055.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | [64.0](/filings/0002019410-26-000016.md) | [31.2](/filings/0002019410-26-000044.md) | [719](/filings/0002019410-25-000012.md) | [753](/filings/0002019410-25-000028.md) | [796](/filings/0002019410-26-000016.md) | [820](/filings/0002019410-26-000044.md) | not reported |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [216](/filings/0002019410-26-000016.md) | not reported | [833](/filings/0002019410-25-000012.md) | [854](/filings/0002019410-25-000028.md) | [998](/filings/0002019410-26-000055.md) | [1,014](/filings/0002019410-26-000044.md) | [1,058](/filings/0002019410-26-000055.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | not reported | [344](/filings/0002019410-26-000016.md) | not reported | [955](/filings/0002019410-25-000012.md) | [985](/filings/0002019410-25-000028.md) | [1,126](/filings/0002019410-26-000055.md) | [1,162](/filings/0002019410-26-000044.md) | [1,230](/filings/0002019410-26-000055.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [165](/filings/0002019410-26-000016.md) | not reported | [90.2](/filings/0002019410-25-000012.md) | [86.0](/filings/0002019410-25-000028.md) | [127](/filings/0002019410-26-000055.md) | [144](/filings/0002019410-26-000044.md) | [191](/filings/0002019410-26-000055.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [621](/filings/0002019410-26-000016.md) | not reported | [502](/filings/0002019410-25-000012.md) | [506](/filings/0002019410-25-000028.md) | [548](/filings/0002019410-26-000055.md) | [569](/filings/0002019410-26-000044.md) | [638](/filings/0002019410-26-000055.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [319](/filings/0002019410-26-000016.md) | not reported | [374](/filings/0002019410-25-000012.md) | [376](/filings/0002019410-25-000028.md) | [379](/filings/0002019410-26-000055.md) | [381](/filings/0002019410-26-000044.md) | [393](/filings/0002019410-26-000055.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | [60.1](/filings/0002019410-26-000016.md) | not reported | [0.1](/filings/0002019410-25-000012.md) | [0.2](/filings/0002019410-25-000028.md) | [0.2](/filings/0002019410-26-000055.md) | [0.2](/filings/0002019410-26-000044.md) | [0.2](/filings/0002019410-26-000055.md) |
| Shareholders' equity | $m | [(1,702)](/filings/0002019410-26-000016.md) | [(2,145)](/filings/0002019410-26-000016.md) | [(2,275)](/filings/0002019410-25-000012.md) | [(2,360)](/filings/0002019410-25-000028.md) | [(2,442)](/filings/0002019410-25-000028.md) | [(2,499)](/filings/0002019410-26-000055.md) | [(2,600)](/filings/0002019410-26-000055.md) | [453](/filings/0002019410-26-000055.md) | [478](/filings/0002019410-25-000028.md) | [577](/filings/0002019410-26-000055.md) | [593](/filings/0002019410-26-000055.md) | [592](/filings/0002019410-26-000055.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(69.4) d](/filings/0002019410-25-000028.md) | [(38.9) d](/filings/0002019410-26-000016.md) | [(31.3)](/filings/0002019410-26-000044.md) | [7.3 d](/filings/0002019410-26-000055.md) | [62.4 d](/filings/0002019410-25-000028.md) | [44.8 d](/filings/0002019410-26-000016.md) | [32.9](/filings/0002019410-26-000044.md) | [28.5 d](/filings/0002019410-26-000055.md) |
| Capital expenditure | $m | [1.8 d](/filings/0002019410-25-000028.md) | [2.3 d](/filings/0002019410-26-000016.md) | [2.7](/filings/0002019410-26-000044.md) | [1.4 d](/filings/0002019410-25-000012.md) | [7.1 d](/filings/0002019410-25-000028.md) | [5.1 d](/filings/0002019410-26-000016.md) | [10.3](/filings/0002019410-26-000044.md) | [22.1 d](/filings/0002019410-26-000055.md) |
| Share repurchases | $m | [0.0 d](/filings/0002019410-25-000028.md) | [0.0 d](/filings/0002019410-26-000016.md) | [0.0](/filings/0002019410-26-000044.md) | [0.0 d](/filings/0002019410-26-000055.md) | [0.0 d](/filings/0002019410-25-000028.md) | [0.1 d](/filings/0002019410-26-000016.md) | [0.0](/filings/0002019410-26-000044.md) | [21.4 d](/filings/0002019410-26-000055.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.4](/filings/0002019410-25-000012.md) | [35.6](/filings/0002019410-25-000028.md) | [35.6](/filings/0002019410-26-000044.md) | [64.9](/filings/0002019410-26-000055.md) | [297](/filings/0002019410-25-000028.md) | [283](/filings/0002019410-26-000044.md) | [283](/filings/0002019410-26-000055.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 282,595,186 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0002019410-26-000055.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.